Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database
Rimple Jeet Kaur,1 Jaykaran Charan,2 Siddhartha Dutta,2 Paras Sharma,3 Pankaj Bhardwaj,4 Praveen Sharma,5 Halyna Lugova,6 Ambigga Krishnapillai,7 Salequl Islam,8 Mainul Haque,9 Sanjeev Misra10 1Department of Pharmacology, Dr. S.N Medical College, Jodhpur, Rajasthan, India; 2Department of Pharmacolog...
Main Authors: | Kaur RJ, Charan J, Dutta S, Sharma P, Bhardwaj P, Lugova H, Krishnapillai A, Islam S, Haque M, Misra S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-12-01
|
Series: | Infection and Drug Resistance |
Subjects: | |
Online Access: | https://www.dovepress.com/favipiravir-use-in-covid-19-analysis-of-suspected-adverse-drug-events--peer-reviewed-article-IDR |
Similar Items
-
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
by: Toru Hifumi, et al.
Published: (2020-08-01) -
Favipiravir in Therapy of Viral Infections
by: Ryta Łagocka, et al.
Published: (2021-01-01) -
Effect of favipiravir and an anti-inflammatory strategy for COVID-19
by: Hitoshi Yamamura, et al.
Published: (2020-07-01) -
Favipiravir: the hidden threat of mutagenic action
by: O. P. Zhirnov, et al.
Published: (2021-05-01) -
Maporal Hantavirus β-Integrin Utilization and Sensitivity to Favipiravir
by: Buys, Kristin K.
Published: (2010)